• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于五种RNA的神经母细胞瘤特征标志物的开发与验证及候选药物鉴定

Development and Validation of a Five-RNA-Based Signature and Identification of Candidate Drugs for Neuroblastoma.

作者信息

Zhang PeiPei, Ma KeXin, Ke XiaoFei, Liu Liu, Li Ying, Liu YaJuan, Wang YouJun

机构信息

Department of Pediatrics, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.

出版信息

Front Genet. 2021 Oct 20;12:685646. doi: 10.3389/fgene.2021.685646. eCollection 2021.

DOI:10.3389/fgene.2021.685646
PMID:34745201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8564070/
Abstract

Neuroblastoma (NBL) originating from the sympathetic nervous system is the most prevalent solid tumor in infancy. Although there is sufficient variability in prognosis among different age pyramids, age-related gene expression profiles and biomarkers remain poorly explored. The present study aimed to construct a signature based on differentially expressed genes (DEGs) between two age groups in NBL. Univariate Cox regression, multivariate Cox regression, and LASSO analyses were used to identify the optimal prognostic factors. The prediction ability of the model was assessed using the receiver operating characteristic (ROC) curve and C-index. Functional enrichment analysis was performed using the Kyoto Encyclopedia of Genes and Genomes and gene ontology databases. A total of 1,160 DEGs were identified between the two groups, and 204 DEGs impacted the survival of NBL. Functional enrichment analysis revealed that the DEGs were involved in retinol metabolism, cholesterol metabolism, and glycolysis/gluconeogenesis pathways. Five RNAs, namely F8A3, PDF, ANKRD24, FAXDC2, and TMEM160 were recruited into the signature. They were correlated with COG risk classification, INSS stage, and histology. MYCN amplification was linked to FAXDC2, TMEM160, PDF, and F8A3. The expression levels of ANKRD24, PDF, and TMEM160 were lower in the hyperdiploid groups. Only FAXDC2 levels were different in the different MKI grades. The ROC curve showed that the five-RNA-based signatures effectively predicted the OS of NBL (3-years AUC = 0.791, 5-years AUC = 0.816) in the TARGET cohort. The predictive capability was also validated by the GSE49711 cohort (3-years AUC = 0.851, 5-years AUC = 0.848). The C-index in the TARGET and GSE49711 cohorts was 0.749 and 0.809, respectively. The potential mechanisms of the five RNAs were also explored gene set enrichment analysis, and candidate drugs targeting the five genes, including dabrafenib, vemurafenib, and bafetinib, were screened. In conclusion, we constructed a five-RNA-based signature to predict the survival of NBL and screened candidate agents against NBL.

摘要

神经母细胞瘤(NBL)起源于交感神经系统,是婴儿期最常见的实体瘤。尽管不同年龄组的预后存在足够的差异,但与年龄相关的基因表达谱和生物标志物仍未得到充分探索。本研究旨在基于NBL两个年龄组之间的差异表达基因(DEG)构建一个特征。使用单变量Cox回归、多变量Cox回归和LASSO分析来确定最佳预后因素。使用受试者工作特征(ROC)曲线和C指数评估模型的预测能力。使用京都基因与基因组百科全书和基因本体数据库进行功能富集分析。两组之间共鉴定出1160个DEG,其中204个DEG影响NBL的生存。功能富集分析表明,这些DEG参与视黄醇代谢、胆固醇代谢和糖酵解/糖异生途径。五个RNA,即F8A3、PDF、ANKRD24、FAXDC2和TMEM160被纳入该特征。它们与COG风险分类、INSS分期和组织学相关。MYCN扩增与FAXDC2、TMEM160、PDF和F8A3相关。在超二倍体组中,ANKRD24、PDF和TMEM160的表达水平较低。在不同的MKI分级中,只有FAXDC2水平不同。ROC曲线显示,基于五个RNA的特征有效地预测了TARGET队列中NBL的总生存期(3年AUC = 0.791,5年AUC = 0.816)。GSE49711队列也验证了该预测能力(3年AUC = 0.851,5年AUC = 0.848)。TARGET和GSE49711队列中的C指数分别为0.749和0.809。还通过基因集富集分析探索了这五个RNA的潜在机制,并筛选了靶向这五个基因的候选药物,包括达拉非尼、维莫非尼和巴非替尼。总之,我们构建了一个基于五个RNA的特征来预测NBL的生存,并筛选了抗NBL的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/dfb00e726492/fgene-12-685646-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/04c25f705235/fgene-12-685646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/11b77ef79ab7/fgene-12-685646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/03c13c215f67/fgene-12-685646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/d402658e3f04/fgene-12-685646-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/5e7d393391c3/fgene-12-685646-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/2e3ac37278d6/fgene-12-685646-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/757b26f640dc/fgene-12-685646-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/dfb00e726492/fgene-12-685646-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/04c25f705235/fgene-12-685646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/11b77ef79ab7/fgene-12-685646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/03c13c215f67/fgene-12-685646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/d402658e3f04/fgene-12-685646-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/5e7d393391c3/fgene-12-685646-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/2e3ac37278d6/fgene-12-685646-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/757b26f640dc/fgene-12-685646-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f54/8564070/dfb00e726492/fgene-12-685646-g008.jpg

相似文献

1
Development and Validation of a Five-RNA-Based Signature and Identification of Candidate Drugs for Neuroblastoma.基于五种RNA的神经母细胞瘤特征标志物的开发与验证及候选药物鉴定
Front Genet. 2021 Oct 20;12:685646. doi: 10.3389/fgene.2021.685646. eCollection 2021.
2
A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.基于五个免疫相关基因的签名预测神经母细胞瘤的生存和免疫特征。
BMC Med Genomics. 2022 Nov 23;15(1):242. doi: 10.1186/s12920-022-01400-y.
3
Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma.基于RNA测序的神经母细胞瘤预后特征的开发与验证
Front Oncol. 2019 Dec 4;9:1361. doi: 10.3389/fonc.2019.01361. eCollection 2019.
4
Comparison of Stage 4 and Stage 4s Neuroblastoma Identifies Autophagy-Related Gene and LncRNA Signatures Associated With Prognosis.4期与4s期神经母细胞瘤的比较确定了与预后相关的自噬相关基因和长链非编码RNA特征。
Front Oncol. 2020 Aug 19;10:1411. doi: 10.3389/fonc.2020.01411. eCollection 2020.
5
Construction and Validation of a 13-Gene Signature for Prognosis Prediction in Medulloblastoma.用于髓母细胞瘤预后预测的13基因特征的构建与验证
Front Genet. 2020 May 19;11:429. doi: 10.3389/fgene.2020.00429. eCollection 2020.
6
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.基于统计分析构建新型膀胱癌 mRNA 特征预测预后模型。
BMC Cancer. 2021 Jul 27;21(1):858. doi: 10.1186/s12885-021-08611-z.
7
Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.构建并验证自噬相关长非编码 RNA 标志物用于预测肾透明细胞癌患者的预后
Cancer Med. 2021 Apr;10(7):2359-2369. doi: 10.1002/cam4.3820. Epub 2021 Mar 2.
8
Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.探索肿瘤免疫相互作用的分子特征,并为神经母细胞瘤开发个体化免疫预后特征。
J Cell Physiol. 2021 Jan;236(1):294-308. doi: 10.1002/jcp.29842. Epub 2020 Jun 8.
9
A novel risk signature that combines 10 long noncoding RNAs to predict neuroblastoma prognosis.一种新型风险特征,结合 10 个长链非编码 RNA 预测神经母细胞瘤预后。
J Cell Physiol. 2020 Apr;235(4):3823-3834. doi: 10.1002/jcp.29277. Epub 2019 Oct 14.
10
Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma.源自MYCN扩增的五基因特征识别及用于预测神经母细胞瘤预后的列线图构建
Front Mol Biosci. 2021 Dec 7;8:769661. doi: 10.3389/fmolb.2021.769661. eCollection 2021.

引用本文的文献

1
Development of a prognostic model for overall survival in neuroblastoma based on Schwann cell-specific genes, clinical predictors, and MYCN amplification.基于施万细胞特异性基因、临床预测指标和MYCN扩增构建神经母细胞瘤总生存预后模型
Transl Cancer Res. 2025 May 30;14(5):2677-2689. doi: 10.21037/tcr-24-2048. Epub 2025 May 26.
2
Identification of GDP as a small inhibitory molecule in HepG2 cells by non‑targeted metabolomics analysis.通过非靶向代谢组学分析鉴定GDP作为HepG2细胞中的一种小分子抑制物。
Oncol Lett. 2025 Feb 11;29(4):178. doi: 10.3892/ol.2025.14924. eCollection 2025 Apr.
3
Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma.

本文引用的文献

1
Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets.神经母细胞瘤中免疫基因和免疫相关长链非编码RNA的预后特征:基于GEO和TARGET数据集的研究
Front Oncol. 2021 Mar 9;11:631546. doi: 10.3389/fonc.2021.631546. eCollection 2021.
2
Neuroblastoma and the epigenome.神经母细胞瘤与表观基因组。
Cancer Metastasis Rev. 2021 Mar;40(1):173-189. doi: 10.1007/s10555-020-09946-y. Epub 2021 Jan 6.
3
Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinoma.
构建甲基化驱动基因相关的预后标志物,并开发神经母细胞瘤新的预后分层策略。
Genes Genomics. 2024 Feb;46(2):171-185. doi: 10.1007/s13258-023-01483-6. Epub 2024 Jan 5.
4
FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells.FAXDC2抑制人肝癌HepG2细胞的增殖和侵袭。
Exp Ther Med. 2023 Nov 22;27(1):27. doi: 10.3892/etm.2023.12315. eCollection 2024 Jan.
5
Comprehensive Transcriptomic Investigation of Rett Syndrome Reveals Increasing Complexity Trends from Induced Pluripotent Stem Cells to Neurons with Implications for Enriched Pathways.雷特综合征的综合转录组学研究揭示了从诱导多能干细胞到神经元的复杂性增加趋势及其对富集通路的影响。
ACS Omega. 2023 Nov 8;8(46):44148-44162. doi: 10.1021/acsomega.3c06448. eCollection 2023 Nov 21.
6
Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature.将多个细胞死亡途径相关风险评分相结合,开发神经母细胞瘤细胞死亡特征。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6513-6526. doi: 10.1007/s00432-023-04605-5. Epub 2023 Feb 13.
7
The Prognostic Role of m6A-Related Genes in Paediatric Neuroblastoma Patients.m6A 相关基因在小儿神经母细胞瘤患者中的预后作用。
Comput Math Methods Med. 2022 Jan 10;2022:8354932. doi: 10.1155/2022/8354932. eCollection 2022.
膀胱尿路上皮癌中RNA结合蛋白的功能及预后意义的综合分析
Am J Transl Res. 2020 Nov 15;12(11):7160-7173. eCollection 2020.
4
Effects of RNA Binding Proteins on the Prognosis and Malignant Progression in Prostate Cancer.RNA结合蛋白对前列腺癌预后及恶性进展的影响
Front Genet. 2020 Oct 20;11:591667. doi: 10.3389/fgene.2020.591667. eCollection 2020.
5
HOPS and p53: thick as thieves in life and death.Hop 与 p53:生死相依。
Cell Cycle. 2020 Nov;19(22):2996-3003. doi: 10.1080/15384101.2020.1838772. Epub 2020 Oct 28.
6
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.全神经母细胞瘤分析揭示了与年龄和特征相关的驱动突变改变。
Nat Commun. 2020 Oct 14;11(1):5183. doi: 10.1038/s41467-020-18987-4.
7
Correlation between the genetic variants of base excision repair (BER) pathway genes and neuroblastoma susceptibility in eastern Chinese children.中国东部儿童碱基切除修复(BER)途径基因的遗传变异与神经母细胞瘤易感性之间的相关性。
Cancer Commun (Lond). 2020 Nov;40(11):641-646. doi: 10.1002/cac2.12088. Epub 2020 Aug 11.
8
Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.状态决定了针对神经母细胞瘤 RAS-MAPK 通路的 SHP2 抑制剂联合治疗的敏感性。
Cancer Res. 2020 Aug 15;80(16):3413-3423. doi: 10.1158/0008-5472.CAN-19-3822. Epub 2020 Jun 25.
9
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.ATR抑制通过多种机制增强PARP抑制剂在高危神经母细胞瘤细胞系中的细胞毒性。
Cancers (Basel). 2020 Apr 28;12(5):1095. doi: 10.3390/cancers12051095.
10
Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.与基因组异常相关的基因特征可预测神经母细胞瘤的预后。
Cancer Commun (Lond). 2020 Mar;40(2-3):105-118. doi: 10.1002/cac2.12016.